Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNAI3 | P08754 | 9/20 | 0.60 |
| ▸ | GNAI1 | P63096 | 9/20 | 0.60 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
| ▸ | GNAO1 | P09471 | 8/20 | 0.54 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.52 |
| ▸ | HTR1A | P08908 | 1/20 | 0.49 |
| ▸ | HTR7 | P34969 | 1/20 | 0.49 |
| ▸ | HRH2 | P25021 | 2/20 | 0.48 |
| ▸ | HRH1 | P35367 | 2/20 | 0.48 |
| ▸ | PAOX | Q6QHF9 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31632752 | 0.92 | GNAI3 (0.65) | GNAI3GNAI1L3MBTL1MEN1KMT2A | |
| SCHEMBL31632758 | 0.92 | GNAI3 (0.65) | GNAI3GNAI1L3MBTL1MEN1KMT2A | |
| SCHEMBL5243155 | 0.91 | GNAI3 (0.72) | GNAI3GNAI1L3MBTL1MEN1KMT2A | |
| SCHEMBL3614951 | 0.89 | GNAI3 (0.61) | GNAI3GNAI1L3MBTL1MEN1KMT2A | |
| SCHEMBL17167936 | 0.89 | GNAI3 (0.65) | GNAI3GNAI1L3MBTL1MEN1KMT2A | |
| SCHEMBL10070849 | 0.89 | GNAI3 (0.60) | GNAI3GNAI1L3MBTL1MEN1KMT2A | |
| SCHEMBL4685413 | 0.86 | GNAI3 (0.58) | GNAI3GNAI1L3MBTL1MEN1KMT2A | |
| SCHEMBL22923584 | 0.85 | GNAI3 (0.65) | GNAI3GNAI1L3MBTL1MEN1KMT2A | |
| SCHEMBL19618199 | 0.85 | HRH2 (0.56) | GNAI3GNAI1L3MBTL1MEN1KMT2A | |
| SCHEMBL25887670 | 0.85 | HRH2 (0.56) | GNAI3GNAI1L3MBTL1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240226343-A1 | NEUROPEPTIDE Y1 RECEPTOR (NPY1R) TARGETED THERAPEUTICS AND USES THEREOF | RADIONETICS ONCOLOGY, INC. | 2024-07-11 | — | — | US | disclosed |
| US-11739076-B2 | Compound or its salt thereof targeting fibroblast activation protein, its preparation methods and its uses thereof | INSTITUTE OF NUCLEAR ENERGY RESEARCH ATOMIC ENERGY COUNCIL, R.O.C. (TW) | 2023-08-29 | — | — | US | disclosed |
| US-20230159495-A1 | COMPOUND OR ITS SALT THEREOF TARGETING FIBROBLAST ACTIVATION PROTEIN, ITS PREPARATION METHODS AND ITS USES THEREOF | INSTITUTE OF NUCLEAR ENERGY RESEARCH ATOMIC ENERGY COUNCIL, R.O.C. (TW) | 2023-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11739076-B2 | Compound or its salt thereof targeting fibroblast activation protein, its preparation methods and its uses thereof | FIBP, FGFR2, FGFR1 | GNAI3 346/4885GNAI1 260/4885L3MBTL1 4440/4885 |
| US-20230159495-A1 | COMPOUND OR ITS SALT THEREOF TARGETING FIBROBLAST ACTIVATION PROTEIN, ITS PREPARATION METHODS AND ITS USES THEREOF | FIBP, FGFR2, FGFR1 | GNAI3 346/4885GNAI1 260/4885L3MBTL1 4440/4885 |
| US-20240226343-A1 | NEUROPEPTIDE Y1 RECEPTOR (NPY1R) TARGETED THERAPEUTICS AND USES THEREOF | NPY1R, NPY2R, NPY4R | GNAI3 1655/4885GNAI1 1458/4885L3MBTL1 2541/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.